Compare APOG & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APOG | IVA |
|---|---|---|
| Founded | 1949 | 2011 |
| Country | United States | France |
| Employees | N/A | 77 |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 976.6M | 883.8M |
| IPO Year | 1994 | N/A |
| Metric | APOG | IVA |
|---|---|---|
| Price | $39.02 | $4.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $47.00 | $16.20 |
| AVG Volume (30 Days) | 340.6K | ★ 1.4M |
| Earning Date | 04-24-2026 | 03-30-2026 |
| Dividend Yield | ★ 3.03% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $1,404,733,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.07 | $751.20 |
| P/E Ratio | $73.69 | ★ N/A |
| Revenue Growth | ★ 3.21 | N/A |
| 52 Week Low | $30.75 | $2.94 |
| 52 Week High | $50.88 | $7.98 |
| Indicator | APOG | IVA |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 60.83 |
| Support Level | $36.90 | $4.45 |
| Resistance Level | $39.06 | $4.67 |
| Average True Range (ATR) | 2.44 | 0.23 |
| MACD | -0.49 | 0.13 |
| Stochastic Oscillator | 1.16 | 94.07 |
Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company geographically operates in the United States, Canada, and Brazil, with the majority revenue generated from the United States.
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.